PORT WASHINGTON, New York, January 14, 2014 /PRNewswire/ --
Equashield (http://www.equashield.com), the leading provider of Closed System Transfer Devices (CSTD) for hazardous drugs, today announced that it has achieved 60% year-over-year sales growth for the fourth straight year.
Equashield's closed systems reduce the risk of exposure for pharmacy technicians, pharmacists, nurses and other medical professionals who prepare and administer hazardous drugs, such as chemotherapy. In addition, the solution helps to prevent microbial ingress, decreasing the risk of infection in patients receiving these drugs.
"Approximately 20% of hospitals and medical centers are already investing in closed systems to ensure their employees' safety," said Marino Kriheli, Product Manager at Equashield. "With growing awareness of the many risks associated with hazardous drug exposure, this market is rapidly growing. In fact, 55% of new customers Equashield acquired this year did not use closed systems previously. Furthermore, with the recent launch of Equashield II, the company's second generation CSTD, we expect major sales growth to continue in 2014 and beyond."
Equashield is the only preassembled closed syringe that requires no further setup, making it quicker and easier to use than other system on the market. Equashield devices are currently used in the Cleveland Clinic, Mt. Sinai Hospital in New York and hundreds of other medical facilities.
Equashield II covers more routes of exposure to hazardous drugs than alternative systems and is the only system that prevents contamination of syringe plungers by hazardous drugs.
"Contamination on syringe plungers has been clearly identified in recent studies, added Kriheli. "The quantities of drug residue found on plungers place this route of exposure among the top risks associated with handling hazardous drugs."
Equashield is a leading developer of closed system drug transfer devices that protect healthcare professionals from hazardous drug and vapor exposure. EQUASHIELD® provides superior safety & ease-of-use by covering more routes of exposure than alternative systems and by enabling faster use than other systems. EQUASHIELD® is clinically proven to eliminate surface contamination with antineoplastic agents and prevent microbial ingress, having demonstrated the ability to extend beyond-use dating for single-use or non-preserved drugs. The system consists of a unique syringe with encapsulated barrel and plunger, built-in closed pressure equalization, and an integrated single motion connector that remains free of drug residue even after multiple connections. EQUASHIELD® is the only preassembled CSTD syringe on the market that requires no further setup, thereby contributing to ease of use and overall hospital productivity. For more information, visit http://www.equashield.com.
Finn Partners for Equashield